Literature DB >> 25982151

Low risk of coronary artery disease in patients with acromegaly.

Cintia Marques Dos Santos Silva1, G A B Lima2, I C M Volschan3, I Gottlieb4, L Kasuki5,6, L Vieira Neto5,7, M R Gadelha8.   

Abstract

The aims of this study are to determine the prevalence of coronary atherosclerosis in acromegalic patients and to investigate the relationship between the coronary artery calcium score (CS) and acromegaly status and clinical parameters [Framingham risk score (FRS)]. Fifty-six acromegalic patients and paired non-acromegalic volunteers were stratified according to the FRS into low-, intermediate-, and high-risk groups. CS was assessed using multidetector computed tomography. The patients were considered to have controlled or active acromegaly at the time they were submitted to evaluation. Sixty-six percent of acromegalic patients exhibited arterial hypertension, 36 % had diabetes mellitus, and 34 % had hypercholesterolemia. The median FRS and the median risk for cardiovascular event within the next 10 years were similar in the acromegalics and the controls. The median total CS and CS >75th percentile didn't differ significantly between these groups. In patients with controlled acromegaly, a low, intermediate, or high FRS risk was observed in 86, 14, and 0 %, respectively. In patients with active disease, a low, intermediate, or high FRS risk was verified in 94, 3, and 3 %, respectively, and differences between the controlled and active groups were not significant. Seventy-two percent of the patients had total CS = 0, and there were no differences between the controlled and active groups. The risk of coronary artery disease in acromegalic patients, determined according to FRS and CS, is low despite the high prevalence of metabolic abnormalities.

Entities:  

Keywords:  Acromegaly; Cardiac disease; Coronary artery calcium score; Framingham risk score

Mesh:

Substances:

Year:  2015        PMID: 25982151     DOI: 10.1007/s12020-015-0628-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  32 in total

Review 1.  Cardiovascular function in acromegaly.

Authors:  R N Clayton
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

Review 2.  Insulin-like growth factor-1 as a vascular protective factor.

Authors:  Elena Conti; Cinzia Carrozza; Ettore Capoluongo; Massimo Volpe; Filippo Crea; Cecilia Zuppi; Felicita Andreotti
Journal:  Circulation       Date:  2004-10-12       Impact factor: 29.690

3.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

Authors:  R B D'Agostino; S Grundy; L M Sullivan; P Wilson
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

4.  [Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly].

Authors:  Alessandra Ferri Casini; Paula Bruna Araújo; Rosita Fontes; Sérgio Salles Xavier; Mônica R Gadelha
Journal:  Arq Bras Endocrinol Metabol       Date:  2006-04-17

5.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

6.  Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.

Authors:  Marta Ragonese; Angela Alibrandi; Gianluca Di Bella; Ignazio Salamone; Soraya Puglisi; Oana Ruxandra Cotta; Maria Luisa Torre; Francesco Ferrau; Rosaria Maddalena Ruggeri; Francesco Trimarchi; Salvatore Cannavo
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

7.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

8.  Investigation of early atherosclerotic changes in acromegalic patients.

Authors:  I Kartal; H Oflaz; B Pamukçu; M Meriç; F Aral; N Ozbey; F Alagöl
Journal:  Int J Clin Pract       Date:  2008-04-16       Impact factor: 2.503

9.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups.

Authors:  Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

10.  Impact of disease duration on coronary calcification in patients with acromegaly.

Authors:  B L Herrmann; M Severing; A Schmermund; C Berg; Th Budde; R Erbel; K Mann
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-04-16       Impact factor: 2.949

View more
  8 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry.

Authors:  Christof Schöfl; David Petroff; Anke Tönjes; Martin Grussendorf; Michael Droste; Günter Stalla; Cornelia Jaursch-Hancke; Sylvère Störmann; Jochen Schopohl
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

3.  Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.

Authors:  Marianna Yaron; Elena Izkhakov; Jessica Sack; Ibrahim Azzam; Etty Osher; Karen Tordjman; Naftali Stern; Yona Greenman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

4.  Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.

Authors:  Dilek Arpaci; Sevim Karakas Celik; Murat Can; Esra Ermiş; Fatih Kuzu; Furuzan Kokturk; Ayse Ceylan Hamamcioglu; Ahmet Dursun; Taner Bayraktaroglu
Journal:  Redox Rep       Date:  2016-02-15       Impact factor: 4.412

5.  Increased Risk of Persistent Glucose Disorders After Control of Acromegaly.

Authors:  Claire Rochette; Thomas Graillon; Frederique Albarel; Isabelle Morange; Henry Dufour; Thierry Brue; Frederic Castinetti
Journal:  J Endocr Soc       Date:  2017-11-24

Review 6.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

Review 7.  Advances in Research on the Cardiovascular Complications of Acromegaly.

Authors:  Han Yang; Huiwen Tan; He Huang; Jianwei Li
Journal:  Front Oncol       Date:  2021-04-02       Impact factor: 6.244

8.  Association of Epicardial Adipose Tissue Thickness with Cardiovascular Risk in Acromegaly.

Authors:  Bulent Can; Fatma Olcay Coskun; Sercin Ozkok; Mumtaz Takir
Journal:  Medeni Med J       Date:  2022-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.